TD Cowen analyst Marc Frahm has maintained their bullish stance on STTK stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marc Frahm has given his Buy rating due to a combination of factors, most notably the emerging profile of SL-325 and its upcoming data catalysts. He highlights that the Phase 1 healthy volunteer study has finished enrolling all single- and multiple-ascending-dose cohorts, with data on safety, pharmacokinetics and dynamics, receptor occupancy, and immunogenicity expected in the second quarter of 2026, which could validate strong target coverage with low anti-drug antibody formation.
He also points to the planned launch of a randomized Phase 2 Crohn’s disease trial in the third quarter of 2026, with the possibility of an additional open-label Phase 2 study in another inflammatory indication that could broaden the opportunity. Combined with preclinical findings that suggest durable DR3 blockade and a potentially differentiated mechanism versus TL1A antibodies, as well as a cash position that supports near-term execution and the prospect of a multi-billion-dollar valuation if the profile is confirmed, these elements underpin his positive stance on Shattuck Labs’ shares.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Agios Pharma, and Revolution Medicines. According to TipRanks, Frahm has an average return of 22.6% and a 52.02% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $14.00 price target.